EssilorLuxottica Rides AI Eyewear Boom Amid Margin Squeeze
Essilorluxottica (OTC) ((ESLOY)) has held its Q4 earnings call. Read on for the main highlights of the call.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EssilorLuxottica’s latest earnings call struck an upbeat tone, underscoring powerful commercial momentum and record financial milestones despite visible margin pressure. Management highlighted surging demand for AI‑powered eyewear, stellar cash generation and progress in myopia management, while acknowledging tariffs, currency swings and lower‑margin wearables as short‑term profit drags.
Record revenue and accelerating year-end growth
EssilorLuxottica delivered record 2025 revenue of €28.5 billion, up 11% at constant currency, with the fourth quarter marking the strongest period of the year. Q4 sales climbed 18.4% at constant rates, or 12.1% on a reported basis, as all major regions posted double‑digit gains and momentum clearly accelerated into year‑end.
Cash generation and balance sheet support firepower
Free cash flow hit an all‑time high of €2.796 billion in 2025, roughly €400 million above the prior year and underscoring robust cash conversion. Net debt to EBITDA finished at 1.7 times, giving the group room to keep investing in growth initiatives and pursue bolt‑on acquisitions without stretching its balance sheet.
AI wearables emerge as a growth engine
The company sold more than 7 million AI and wearable glasses in 2025, fueling triple‑digit growth in the frames segment, particularly for Ray‑Ban and Oakley. Management stressed attractive attachment economics, with about 20% of AI glasses paired with prescription lenses and 40–50% featuring transition coatings, supporting revenue and future price/mix upside.
Stellest drives leadership in myopia management
Myopia management revenue grew 22% in 2025, led by Stellest, which is currently the only spectacle lens with U.S. FDA authorization. The new Stellest 2.0 lens in China showed roughly twice the reduction in axial length growth over 12 months versus its predecessor, and myopia already accounts for about 27% of Greater China revenue.
Geographic breadth underpins topline resilience
Growth was broadly based, with fourth‑quarter constant‑currency sales up 23.8% in North America, 15.7% in EMEA and 11.6% in Asia‑Pacific, while Latin America added 7.6%. Key markets such as Italy, Spain, the U.K., Turkey, India and Australia all delivered double‑digit Q4 gains, showcasing the strength of the company’s multi‑brand, multi‑channel footprint.
Brand power and product launches fuel demand
Strategic brand moves supported the revenue surge, including an extended Burberry license through 2035 and a new collaboration with MIU MIU. The company also leaned on cultural and sporting visibility, naming A$AP Rocky as Ray‑Ban creative director and celebrating Oakley’s 50th anniversary with Winter Olympics exposure and launches like Oakley Vanguard and Ray‑Ban Meta Display.
R&D and sustainability bolster long-term positioning
EssilorLuxottica formed a Scientific Advisory Committee of leading experts and stepped up investments in oculomics, med‑tech, chip partnerships and smart eyewear labs. On sustainability, it earned an ‘A’ climate rating from CDP and a score of 66 in S&P Global’s Corporate Sustainability Assessment, ranking third in its industry and reinforcing its ESG credentials.
Updated five-year roadmap targets aligned profit and sales
Management updated its five‑year roadmap, aiming for revenues and operating profit to grow broadly in tandem as scale and price/mix improvements kick in. The plan rests on higher‑value lenses, services and maturing wearables contributing more to margins over time, as early‑stage investments transition into more profitable, scaled businesses.
Gross margin squeezed by tariffs and product mix
Gross margin declined about 260 basis points year‑on‑year, with roughly one‑third of the impact attributed to U.S. tariffs. The remaining two‑thirds came from product‑mix dilution as AI glasses, which currently carry lower margins, grew rapidly and accounted for a significant share of the second‑half margin compression.
Operating and net margin moderation
Operating profit margin fell around 70 basis points at constant currency, or roughly 100 basis points on a reported basis after FX effects. Net profit margin slipped about 50 basis points at constant rates, or 70 basis points reported, as lower gross margins, tariffs, adverse FX and higher interest expenses offset the benefit of lower OpEx as a share of sales.
Tariff and FX headwinds add external drag
The company quantified a combined €300 million hit to adjusted operating profit from U.S. tariffs and weaker foreign currencies. Q4 highlighted the gap, with about six percentage points difference between constant‑currency and reported growth as the U.S. dollar weakened roughly eight percentage points against the euro, and management cautioned that some of these headwinds may linger into 2026.
Higher financing costs weigh below the line
Rising interest rates pushed up the group’s cost of debt, adding pressure below the operating profit line and contributing to the softer net margin. While leverage remains modest, management acknowledged that the higher‑rate backdrop is a non‑trivial factor in overall earnings performance versus prior low‑rate years.
Wearables’ growth comes with near-term dilution
Management noted that booming AI wearables were a key driver of gross margin dilution, especially in the second half, given their currently lower margin profile. Upfront operating and capital expenditures in wearables and R&D further weighed on profitability, though the company expects unit economics to improve as volumes scale and the product portfolio evolves.
Mixed performance across channels and products
Not all parts of the business fired equally, with North American e‑commerce partner sales turning negative in the fourth quarter and the region’s lens business essentially flat. Some markets, including France with low single‑digit growth and Korea in the mid‑single digits, lagged the broader group performance, underscoring ongoing optimization needs.
Guidance points to growth with staged margin recovery
Looking ahead, EssilorLuxottica reiterated that it is on track with its long‑term outlook and five‑year plan for aligned revenue and operating profit growth. Management guided for continued investment in med‑tech and wearables, gradual margin recovery as these scale, and an annualization of tariff and FX headwinds into 2026, with a mid‑year progress review after a strong double‑digit start to January.
EssilorLuxottica’s earnings call painted the picture of a growth machine facing manageable growing pains rather than structural issues. Investors are being asked to tolerate near‑term margin pressure as AI wearables and myopia solutions scale, in exchange for a larger, more diversified and increasingly tech‑driven eyewear leader over the medium term.
